Dysregulation of monocyte biology in metabolic syndrome

References

• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120(16):1640-5
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112(17):2735-52
   PubMed Web of Science ®Google Scholar
• Mozumdar A, Liguori G. Persistent increase of prevalence of metabolic syndrome among US adults: NHANES III to NHANES 1999-2006. Diab Care 2011;34(1):216-19
   PubMed Web of Science ®Google Scholar
• Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15(7):539-53
   PubMed Web of Science ®Google Scholar
• Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010;56(14):1113-32
   PubMed Web of Science ®Google Scholar
• Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288(21):2709-16
   PubMed Web of Science ®Google Scholar
• Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52(5):1210-14
   PubMed Web of Science ®Google Scholar
• Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008;75(10):721-8
   PubMed Web of Science ®Google Scholar
• Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004;33(2):431-53. table of contents
   Google Scholar
• Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342(12):836-43
   PubMed Web of Science ®Google Scholar
• Yudkin JS, Juhan-Vague I, Hawe E, et al. Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. Metabolism 2004;53(7):852-7
   Google Scholar
• Bremer AA, Jialal I. Adipose tissue dysfunction in nascent metabolic syndrome. J Obes 2013;2013:393192
   PubMedGoogle Scholar
• Ghanim H, Aljada A, Hofmeyer D, et al. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004;110(12):1564-71
   PubMed Web of Science ®Google Scholar
• Jialal I, Kaur H, Devaraj S. Toll-like receptor status in obesity and metabolic syndrome: a translational perspective. J Clin Endocrinol Metab 2014;99:39-48
   PubMed Web of Science ®Google Scholar
• Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102(1):42-7
   PubMed Web of Science ®Google Scholar
• Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325(5940):612-16
   PubMed Web of Science ®Google Scholar
• Roitt I, Brostoff J, Male D. editors. Immunology. Mosby; London, UK: 2001
   Google Scholar
• Ziegler-Heitbrock L, Ancuta P, Crowe S, et al. Nomenclature of monocytes and dendritic cells in blood. Blood 2010;116(16):e74-80
   PubMed Web of Science ®Google Scholar
• Liang CP, Han S, Senokuchi T, Tall AR. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res 2007;100(11):1546-55
   Google Scholar
• MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-50
   PubMed Web of Science ®Google Scholar
• Jialal I, Devaraj S, Adams-Huet B, et al. Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome. J Clin Endocrinol Metab 2012;97(10):E1844-50
   Google Scholar
• Devaraj S, Chen X, Adams-Huet B, Jialal I. Increased expression of Fc-gamma receptors on monocytes in patients with nascent metabolic syndrome. J Clin Endocrinol Metab 2013;98(9):E1510-15
   Google Scholar
• Kaur H, Adams-Huet B, Smith G, Jialal I. Increased neutrophil count in nascent metabolic syndrome. Metab Syndr Relat Disord 2013;11(2):128-31
   Google Scholar
• Jialal I, Huet BA, Kaur H, et al. Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care 2012;35(4):900-4
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001;89(12):1092-103
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci 2001;58(1):4-43
   PubMed Web of Science ®Google Scholar
• Mach F, Schonbeck U, Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 1998;137(Suppl):S89-95
   Google Scholar
• Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996;156(10):3952-60
   PubMed Web of Science ®Google Scholar
• Schonbeck U, Varo N, Libby P, et al. Soluble CD40L and cardiovascular risk in women. Circulation 2001;104(19):2266-8
   PubMed Web of Science ®Google Scholar
• Jinchuan Y, Zonggui W, Jinming C, et al. Upregulation of CD40–CD40 ligand system in patients with diabetes mellitus. Clin Chim Acta 2004;339(1-2):85-90
   Google Scholar
• Natal C, Restituto P, Inigo C, et al. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J Clin Endocrinol Metab 2008;93(6):2319-27
   Google Scholar
• Erridge C. The roles of Toll-like receptors in atherosclerosis. J Innate Immun 2009;1(4):340-9
   PubMed Web of Science ®Google Scholar
• Jialal I, Kaur H. The role of toll-like receptors in diabetes-induced inflammation: implications for vascular complications. Curr Diab Rep 2012. [Epub ahead of print]
   Google Scholar
• Miller YI, Viriyakosol S, Binder CJ, et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003;278(3):1561-8
   Google Scholar
• Hardy OT, Kim A, Ciccarelli C, et al. Increased Toll-like receptor (TLR) mRNA expression in monocytes is a feature of metabolic syndrome in adolescents. Pediatr Obes 2013;8(1):e19-23
   Google Scholar
• Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005;25(7):1359-63
   Google Scholar
• D'Amore S, Vacca M, Graziano G, et al. Nuclear receptors expression chart in peripheral blood mononuclear cells identifies patients with Metabolic Syndrome. Biochim Biophys Acta 2013;1832(12):2289-301
   Google Scholar
• Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood 2006;108(4):1388-94
   Google Scholar
• Wellen KE, Fucho R, Gregor MF, et al. Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 2007;129(3):537-48
   Google Scholar
• Wang ZH, Zhang W, Gong HP, et al. Expression of STAMP2 in monocytes associates with cardiovascular alterations. Eur J Clin Invest 2010;40(6):490-6
   Google Scholar
• Loughrey BV, McGinty A, Young IS, et al. Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low-dose atorvastatin treatment: evidence from a randomized controlled trial. Clin Endocrinol (Oxf) 2012. [Epub ahead of print]
   Google Scholar
• Nakagomi A, Sasaki M, Ishikawa Y, et al. Upregulation of monocyte tissue factor activity is significantly associated with low-grade chronic inflammation and insulin resistance in patients with metabolic syndrome. Circ J 2010;74(3):572-7
   Google Scholar
• Nakagomi A, Sasaki M, Ishikawa Y, et al. Upregulation of monocyte tissue factor activity is significantly associated with carotid intima-media thickness in patients with metabolic syndrome. J Atheroscler Thromb 2011;18(6):475-86
   Google Scholar
• Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107(3):398-404
   PubMed Web of Science ®Google Scholar
• Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006;26(10):2200-7
   PubMed Web of Science ®Google Scholar
• Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the third national health and nutrition examination survey. Atherosclerosis 2003;168(2):351-8
   PubMed Web of Science ®Google Scholar
• Hulsmans M, Geeraert B, De Keyzer D, et al. Interleukin-1 receptor-associated kinase-3 is a key inhibitor of inflammation in obesity and metabolic syndrome. PLoS One 2012;7(1):e30414
   PubMed Web of Science ®Google Scholar
• Hulsmans M, Sinnaeve P, Van der Schueren B, et al. Decreased miR-181a expression in monocytes of obese patients is associated with the occurrence of metabolic syndrome and coronary artery disease. J Clin Endocrinol Metab 2012;97(7):E1213-18
   Web of Science ®Google Scholar
• Azfer A, Niu J, Rogers LM, et al. Activation of endoplasmic reticulum stress response during the development of ischemic heart disease. Am J Physiol Heart Circ Physiol 2006;291(3):H1411-20
   Google Scholar
• Sage AT, Holtby-Ottenhof S, Shi Y, et al. Metabolic syndrome and acute hyperglycemia are associated with endoplasmic reticulum stress in human mononuclear cells. Obesity (Silver Spring) 2012;20(4):748-55
   Google Scholar
• Houstis N, Rosen ED, Lander ES. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006;440(7086):944-8
   PubMed Web of Science ®Google Scholar
• Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114(12):1752-61
   PubMed Web of Science ®Google Scholar
• Mangge H, Schauenstein K, Stroedter L, et al. Low grade inflammation in juvenile obesity and type 1 diabetes associated with early signs of atherosclerosis. Exp Clin Endocrinol Diabetes 2004;112(7):378-82
   Google Scholar
• Esposito K, Ciotola M, Schisano B, et al. Oxidative stress in the metabolic syndrome. J Endocrinol Invest 2006;29(9):791-5
   Google Scholar
• Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004;89(10):4963-71
   PubMed Web of Science ®Google Scholar
• Sjogren P, Basu S, Rosell M, et al. Measures of oxidized low-density lipoprotein and oxidative stress are not related and not elevated in otherwise healthy men with the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005;25(12):2580-6
   Google Scholar
• Yubero-Serrano EM, Delgado-Lista J, Pena-Orihuela P, et al. Oxidative stress is associated with the number of components of metabolic syndrome: LIPGENE study. Exp Mol Med 2013;45:e28
   PubMedGoogle Scholar
• Jang SY, Kim SY, Bae YS. p53 deacetylation by SIRT1 decreases during protein kinase CKII downregulation-mediated cellular senescence. FEBS Lett 2011;585(21):3360-6
   Google Scholar
• Leibiger IB, Berggren PO. Sirt1: a metabolic master switch that modulates lifespan. Nat Med 2006;12(1):34-6. discussion 36
   Web of Science ®Google Scholar
• Rajamohan SB, Pillai VB, Gupta M, et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol Cell Biol 2009;29(15):4116-29
   PubMed Web of Science ®Google Scholar
• Higashida K, Kim SH, Jung SR, et al. Effects of resveratrol and SIRT1 on PGC-1alpha activity and mitochondrial biogenesis: a reevaluation. PLoS Biol 2013;11(7):e1001603
   PubMed Web of Science ®Google Scholar
• Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004;429(6993):771-6
   PubMed Web of Science ®Google Scholar
• Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006;4(2):e31
   PubMed Web of Science ®Google Scholar
• Aquilano K, Vigilanza P, Baldelli S, et al. Peroxisome proliferator-activated receptor gamma co-activator 1alpha (PGC-1alpha) and sirtuin 1 (SIRT1) reside in mitochondria: possible direct function in mitochondrial biogenesis. J Biol Chem 2010;285(28):21590-9
   PubMed Web of Science ®Google Scholar
• de Kreutzenberg SV, Ceolotto G, Papparella I, et al. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2010;59(4):1006-15
   PubMed Web of Science ®Google Scholar
• Fortuno A, San Jose G, Moreno MU, et al. Phagocytic NADPH oxidase overactivity underlies oxidative stress in metabolic syndrome. Diabetes 2006;55(1):209-15
   Google Scholar
• Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004;24(5):816-23
   PubMed Web of Science ®Google Scholar
• Devaraj S, Jialal I. Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. Circulation 2000;102(2):191-6
   Google Scholar
• Bokoch GM, Knaus UG. NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci 2003;28(9):502-8
   PubMed Web of Science ®Google Scholar
• Vavrova L, Kodydkova J, Zeman M, et al. Altered activities of antioxidant enzymes in patients with metabolic syndrome. Obes Facts 2013;6(1):39-47
   PubMed Web of Science ®Google Scholar
• Ziobro A, Duchnowicz P, Mulik A, et al. Oxidative damages in erythrocytes of patients with metabolic syndrome. Mol Cell Biochem 2013;378(1-2):267-73
   PubMed Web of Science ®Google Scholar
• Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116
   PubMed Web of Science ®Google Scholar
• Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004;10(11):549-57
   PubMed Web of Science ®Google Scholar
• Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD, et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc Natl Acad Sci USA 2004;101(7):2040-5
   PubMed Web of Science ®Google Scholar
• Kwak MK, Wakabayashi N, Itoh K, et al. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 2003;278(10):8135-45
   PubMed Web of Science ®Google Scholar
• Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc Natl Acad Sci USA 2001;98(8):4611-16
   PubMed Web of Science ®Google Scholar
• Zhang Q, Pi J, Woods CG, Andersen ME. A systems biology perspective on Nrf2-mediated antioxidant response. Toxicol Appl Pharmacol 2010;244(1):84-97
   PubMed Web of Science ®Google Scholar
• Tan Y, Ichikawa T, Li J, et al. Diabetic downregulation of Nrf2 activity via ERK contributes to oxidative stress-induced insulin resistance in cardiac cells in vitro and in vivo. Diabetes 2011;60(2):625-33
   PubMed Web of Science ®Google Scholar
• Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005;579(4):859-62
   PubMed Web of Science ®Google Scholar
• Rentoukas E, Tsarouhas K, Kaplanis I, et al. Connection between telomerase activity in PBMC and markers of inflammation and endothelial dysfunction in patients with metabolic syndrome. PLoS One 2012;7(4):e35739
   PubMed Web of Science ®Google Scholar
• Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006;91(11):4489-96
   Web of Science ®Google Scholar
• Lee IT, Lee WJ, Ou HC, et al. Metabolic syndrome abating the beneficial effect of pravastatin treatment on adhesion of endothelium by monocytes in subjects with hypercholesterolemia. Metabolism 2009;58(3):416-20
   Google Scholar
• Aydin M, Onuk T, Dogan SM, et al. [The effect of statin treatment on inflammation in patients with metabolic syndrome]. Turk Kardiyol Dern Ars 2009;37(1):26-34
   Google Scholar
• Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109(17):2054-7
   PubMed Web of Science ®Google Scholar
• Bahr IN, Tretter P, Kruger J, et al. High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-gamma target genes in patients with the metabolic syndrome. Hypertension 2011;58(4):725-32
   Google Scholar
• de Mello VD, Kolehmainen M, Pulkkinen L, et al. Downregulation of genes involved in NFkappaB activation in peripheral blood mononuclear cells after weight loss is associated with the improvement of insulin sensitivity in individuals with the metabolic syndrome: the GENOBIN study. Diabetologia 2008;51(11):2060-7
   PubMed Web of Science ®Google Scholar